522P - Galectin 3 binding protein as potential biomarker in glioma diagnosis

Background

Gliomas, or malignant brain tumors that grow from glial cells, are the most prevalent form. They account for roughly 40% of all primary brain tumors and 70% of all primary malignant brain tumors. The only procedures available for diagnosing different stages of glioma are surgical incision and biopsy; however, our work focuses on finding a minimally invasive way for early glioma diagnosis. Identification of proteins released by cancer cells is of particular interest in this area, as it could lead to a better understanding of tumor growth.

Methods

Extracellular vesicles (EVs) were extracted from pooled plasma of healthy individuals (n=03) and glioma patients of various grades (Grade I, II, or III). The size and concentration of Plasma derived-EVs marker were determined using nanoparticle tracking analysis, immunohistochemistry, western blot, and flow cytometry. In furthermore, an iTRAQ-based LC-MS/MS analysis of EVs protein was performed. The candidate protein galectin-3 binding protein was validated using ELISA and other methods (LGALS3BP).

Results

Total 123 proteins were identified from plasma derived pooled EVs and 34, 12 and 14 proteins were found to be differentially abundant by more than 1.3 in the different grades of glioma grade I, pilocytic astrocytoma; grade II, diffuse astrocytoma; grade III, anaplastic astrocytoma, respectively, in comparison with the control samples. A total of seven proteins-namely, CRP, SAA2, SERPINA3, SAA1, C4A, LV211, and LGALS3BP-showed differential abundance in all the three grades. LGALS3BP is the only protein which found to be strikingly high in all three grades in a progressive manner. Further ELISA and immunohistochemistry technique implemented to verify LGALS3BP in cohort of samples.

Conclusions

LGALS3BP was shown to be elevated across all grades, and ELISA analysis of individual blood plasma and plasma-derived extracellular vesicles validated the enhanced expression of LGALS3BP in glioma patients. That shows the possible biomarker for early diagnosis of glioma and improved patient survival. This study would further provides the information of progression and monitoring the tumor grades (grade I, grade II, grade III).

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The author.

Funding

Has not received any funding.

Disclosure

The author has declared no conflicts of interest.